Correction: Therapeutic efficacy of immune-oncology combination therapy in advanced renal cell carcinoma without prior nephrectomy.
Kosuke Ueda; Naoki Ito; Yuya Sakai; Satoshi Ohnishi; Taishi Hirano; Hirofumi Kurose; Katsuaki Chikui; Keiichiro Uemura; Kiyoaki Nishihara; Makoto Nakiri; Shigetaka Suekane; Tsukasa Igawa
International journal of clinical oncology, 2025年03月01日

Therapeutic efficacy of immune-oncology combination therapy in advanced renal cell carcinoma without prior nephrectomy.
Kosuke Ueda; Naoki Ito; Yuya Sakai; Satoshi Ohnishi; Taishi Hirano; Hirofumi Kurose; Katsuaki Chikui; Keiichiro Uemura; Kiyoaki Nishihara; Makoto Nakiri; Shigetaka Suekane; Tsukasa Igawa
International journal of clinical oncology, 2025年02月03日

Efficacy and Safety of Nivolumab With Ipilimumab in Elderly Patients With Advanced Renal Cell Carcinoma.
Kosuke Ueda; Naoki Ito; Yuya Sakai; Satoshi Ohnishi; Taishi Hirano; Hirofumi Kurose; Katsuaki Chikui; Keiichiro Uemura; Kiyoaki Nishihara; Makoto Nakiri; Shigetaka Suekane; Tsukasa Igawa
Anticancer research, 2024年11月

Effects of long-term desmopressin treatment for nocturia in older people.
Hirofumi Kurose; Kosuke Ueda; Katsuaki Chikui; Keiichiro Uemura; Kiyoaki Nishihara; Makoto Nakiri; Shigetaka Suekane; Tsukasa Igawa
International journal of urology : official journal of the Japanese Urological Association, 2024年10月

PSA doubling time 4.65 months as an optimal cut-off of Japanese nonmetastatic castration-resistant prostate cancer.
Shinichi Sakamoto; Kodai Sato; Takahiro Kimura; Yoshiyuki Matsui; Yusuke Shiraishi; Kohei Hashimoto; Hideaki Miyake; Shintaro Narita; Jun Miki; Ryuji Matsumoto; Takuma Kato; Toshihiro Saito; Ryotaro Tomida; Masaki Shiota; Akira Joraku; Naoki Terada; Shigetaka Suekane; Tomoyuki Kaneko; Shuichi Tatarano; Yuko Yoshio; Takayuki Yoshino; Naotaka Nishiyama; Eiryo Kawakami; Tomohiko Ichikawa; Hiroshi Kitamura
Scientific reports, 2024年07月03日

TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor-Naïve Locally Advanced or Metastatic Urothelial Carcinoma.
Hiroyuki Nishiyama; Junji Yonese; Takashi Kawahara; Ryuji Matsumoto; Hideaki Miyake; Nobuaki Matsubara; Hiroji Uemura; Masatoshi Eto; Haruhito Azuma; Wataru Obara; Akito Terai; Satoshi Fukasawa; Shigetaka Suekane
Molecular cancer therapeutics, 2024年04月02日

GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone-sensitive prostate cancer; KYUCOG-1401.
Akira Yokomizo; Masaki Shiota; Futoshi Morokuma; Masatoshi Eto; Hideyasu Matsuyama; Hiroaki Matsumoto; Toshiyuki Kamoto; Naoki Terada; Kazuya Kawahara; Hideki Enokida; Shuichi Tatarano; Naohiro Fujimoto; Katsuyoshi Higasijima; Hideki Sakai; Tomoaki Hakariya; Tsukasa Igawa; Shigetaka Suekane; Tomomi Kamba; Yutaka Sugiyama; Junji Kishimoto; Seiji Naito
International journal of urology : official journal of the Japanese Urological Association, 2024年04月

Soluble Immune Checkpoint Molecules as Predictors of Efficacy in Immuno-Oncology Combination Therapy in Advanced Renal Cell Carcinoma.
Kosuke Ueda; Keiichiro Uemura; Naoki Ito; Yuya Sakai; Satoshi Ohnishi; Hiroki Suekane; Hirofumi Kurose; Tasuku Hiroshige; Katsuaki Chikui; Kiyoaki Nishihara; Makoto Nakiri; Shigetaka Suekane; Sachiko Ogasawara; Hirohisa Yano; Tsukasa Igawa
Current oncology (Toronto, Ont.), 2024年03月22日

[EFFICACY AND SAFETY OF ENFORTUMAB VEDOTIN IN ADVANCED UROTHELIAL CARCINOMA TREATMENT: AN INITIAL EXPERIENCE IN A SINGLE INSTITUTION].
Kiyoaki Nishihara; Hirofumi Kurose; Naoki Ito; Satoshi Ohnishi; Taishi Hirano; Hiroki Suekane; Kouta Watanabe; Katsuaki Chikui; Kosuke Ueda; Kei-Ichiro Uemura; Makoto Nakiri; Shigetaka Suekane; Tsukasa Igawa
Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2024年

Determining the optimal initial dose for Japanese patients with nocturnal polyuria using an initial dose of desmopressin 50 μg.
Hirofumi Kurose; Keisuke Komiya; Naoyuki Ogasawara; Kosuke Ueda; Katsuaki Chikui; Kiyoaki Nishihara; Makoto Nakiri; Mitsunori Matsuo; Shigetaka Suekane; Tsukasa Igawa
Lower urinary tract symptoms, 2023年05月

Sarcopenia and excess visceral fat accumulation negatively affect early urinary function after I-125 low-dose-rate brachytherapy for localized prostate cancer.
Naoyuki Ogasawara; Makoto Nakiri; Hirofumi Kurose; Kosuke Ueda; Katsuaki Chikui; Kiyoaki Nishihara; Mitsunori Matsuo; Shigetaka Suekane; Yoshitaka Morimatsu; Kenta Murotani; Koichiro Muraki; Chikayuki Hattori; Etsuyo Ogo; Tatsuya Ishitake; Tsukasa Igawa
International journal of urology : official journal of the Japanese Urological Association, 2023年04月

Prognostic Value of Absolute Lymphocyte Count in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab Plus Ipilimumab.
Kosuke Ueda; Naoyuki Ogasawara; Naoki Ito; Satoshi Ohnishi; Hiroki Suekane; Hirofumi Kurose; Tasuku Hiroshige; Katsuaki Chikui; Keiichiro Uemura; Kiyoaki Nishihara; Makoto Nakiri; Shigetaka Suekane; Tsukasa Igawa
Journal of clinical medicine, 2023年03月21日

Discontinuation of pembrolizumab for advanced urothelial carcinoma without disease progression: Nationwide cohort study.
Katsuhiro Ito; Yuki Kita; Akira Yokomizo; Jun Miki; Yuko Yoshio; Hiroaki Matsumoto; Takehiko Segawa; Takashi Karashima; Naotaka Nishiyama; Kazuto Imai; Shigetaka Suekane; Seiji Nagasawa; Shin Higashi; Hiroyuki Nishiyama; Hiroshi Kitamura; Takashi Kobayashi
Cancer medicine, 2023年02月

Sarcopenia and the Therapeutic Effects of Androgen Receptor-axis-targeted Therapies in Patients With Castration-resistant Prostate Cancer.
Tasuku Hiroshige; Naoyuki Ogasawara; Hisaji Kumagae; Kosuke Ueda; Katsuaki Chikui; Kei-Ichiro Uemura; Kiyoaki Nishihara; Makoto Nakiri; Mitsunori Matsuo; Shigetaka Suekane; Tsukasa Igawa
In vivo (Athens, Greece), 2023年

Investigation of Effect Predictors of Desmopressin in Nocturia Patients With Nocturnal Polyuria.
Hirofumi Kurose; Naoyuki Ogasawara; Kosuke Ueda; Katsuaki Chikui; Keiichiro Uemura; Kiyoaki Nishihara; Makoto Nakiri; Shigetaka Suekane; Tsukasa Igawa
In vivo (Athens, Greece), 2023年

Improved Survival of Real-world Japanese Patients With Advanced Renal Cell Carcinoma Treated With Immuno-oncology Combination Therapy.
Kosuke Ueda; Shigetaka Suekane; Hirofumi Kurose; Naoki Ito; Naoyuki Ogasawara; Tasuku Hiroshige; Katsuaki Chikui; Kazuhisa Ejima; Keiichiro Uemura; Makoto Nakiri; Kiyoaki Nishihara; Mitsunori Matsuo; Tsukasa Igawa
Anticancer research, 2022年09月

Radiotherapy plus androgen deprivation therapy for prostate-specific antigen persistence in lymph node-positive prostate cancer.
Masaki Shiota; Dai Takamatsu; Takahiro Kimura; Kojiro Tashiro; Yoshiyuki Matsui; Ryotaro Tomida; Ryoichi Saito; Masakazu Tsutsumi; Akira Yokomizo; Yoshiyuki Yamamoto; Kohei Edamura; Makito Miyake; Shuichi Morizane; Takayuki Yoshino; Akihiro Matsukawa; Shintaro Narita; Ryuji Matsumoto; Takashi Kasahara; Kohei Hashimoto; Hiroaki Matsumoto; Masashi Kato; Shusuke Akamatsu; Akira Joraku; Manabu Kato; Takahiro Yamaguchi; Toshihiro Saito; Tomoyuki Kaneko; Atsushi Takahashi; Takuma Kato; Shinichi Sakamoto; Hideki Enokida; Hidenori Kanno; Naoki Terada; Shigetaka Suekane; Naotaka Nishiyama; Masatoshi Eto; Hiroshi Kitamura
Cancer science, 2022年07月

Immune responses of patients without cancer recurrence after a cancer vaccine over a long term.
Shigetaka Suekane; Shigeru Yutani; Uhi Toh; Koichi Yoshiyama; Kyogo Itoh
Molecular and clinical oncology, 2022年06月

Immune-related adverse events are clinical biomarkers to predict favorable outcomes in advanced renal cell carcinoma treated with nivolumab plus ipilimumab.
Kosuke Ueda; Shigetaka Suekane; Hirofumi Kurose; Naoki Ito; Naoyuki Ogasawara; Tasuku Hiroshige; Katsuaki Chikui; Kazuhisa Ejima; Keiichiro Uemura; Makoto Nakiri; Kiyoaki Nishihara; Tsukasa Igawa
Japanese journal of clinical oncology, 2022年05月05日

Impact of Gleason score of the tumor at the positive surgical margin as a prognostic factor.
Hirofumi Kurose; Kosuke Ueda; Naoyuki Ogasawara; Katsuaki Chikui; Makoto Nakiri; Kiyoaki Nishihara; Mitsunori Matsuo; Shigetaka Suekane; Hironori Kusano; Jun Akiba; Hirohisa Yano; Tsukasa Igawa
Molecular and clinical oncology, 2022年04月

Survival outcomes of non-definitive therapy for muscle-invasive bladder cancer.
Kiyoaki Nishihara; Kosuke Ueda; Hirofumi Kurose; Naoyuki Ogasawara; Tasuku Hiroshige; Katsuaki Chikui; Kazuhisa Ejima; Keiichiro Uemura; Makoto Nakiri; Shigetaka Suekane; Tsukasa Igawa
Oncology letters, 2022年04月

Absolute lymphocyte count is an independent predictor of survival in patients with metastatic renal cell carcinoma treated with nivolumab.
Kosuke Ueda; Shigetaka Suekane; Hirofumi Kurose; Naoyuki Ogasawara; Tasuku Hiroshige; Katsuaki Chikui; Keiichiro Uemura; Makoto Nakiri; Kiyoaki Nishihara; Mitsunori Matsuo; Tsukasa Igawa
Japanese journal of clinical oncology, 2022年02月05日

[EFFICACY AND SAFETY OF INITIAL DESMOPRESSIN DOSE OF 50 μg IN ELDERLY MALE PATIENTS WITH NOCTURNAL POLYURIA].
Hirofumi Kurose; Keisuke Komiya; Naoyuki Ogasawara; Kosuke Ueda; Katsuaki Chikui; Kiyoaki Nishihara; Makoto Nakiri; Mitsunori Matsuo; Shigetaka Suekane; Tsukasa Igawa
Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2022年

Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR.
Takashi Kobayashi; Katsuhiro Ito; Takahiro Kojima; Satoru Maruyama; Shoichiro Mukai; Masakazu Tsutsumi; Jun Miki; Tomoya Okuno; Yuko Yoshio; Hiroaki Matsumoto; Toru Shimazui; Takehiko Segawa; Takashi Karashima; Kimihiko Masui; Fumimasa Fukuta; Kojiro Tashiro; Kazuto Imai; Shigetaka Suekane; Seiji Nagasawa; Shin Higashi; Tomohiro Fukui; Osamu Ogawa; Hiroshi Kitamura; Hiroyuki Nishiyama
Cancer immunology, immunotherapy : CII, 2021年07月07日

Phase I/II study to evaluate the efficacy of TAS0313, a cancer peptide vaccine, combined with pembrolizumab for locally advanced or metastatic urothelial carcinoma.
Ryuji Matsumoto; Junji Yonese; Takashi Kawahara; Hideaki Miyake; Nobuaki Matsubara; Hiroji Uemura; Masatoshi Eto; Haruhito Azuma; Wataru Obara; Akito Terai; Satoshi Fukasawa; Shigetaka Suekane; Hiroyuki Nishiyama
JOURNAL OF CLINICAL ONCOLOGY, 2021年05月

Longitudinal Changes in Health-related Quality of Life After 125I Low-dose-rate Brachytherapy for Localized Prostate Cancer.
Naoyuki Ogasawara; Makoto Nakiri; Hirofumi Kurose; Kosuke Ueda; Katsuaki Chikui; Kiyoaki Nishihara; Mitsunori Matsuo; Shigetaka Suekane; Kenta Murotani; Koichiro Muraki; Chikayuki Hattori; Etsuyo Ogo; Tukasa Igawa; Tatsuya Ishitake
Anticancer research, 2020年11月

Synchronous primary triple urogenital malignant tumors of kidney, prostate and bladder.
Hirofumi Kurose; Kosuke Ueda; Makoto Nakiri; Mitsunori Matsuo; Shigetaka Suekane; Tsukasa Igawa
Urology case reports, 2020年11月

High postoperative neutrophil-to-lymphocyte ratio as a poor prognostic marker in patients with upper tract urothelial carcinoma.
Kiyoaki Nishihara; Shigetaka Suekane; Kousuke Ueda; Makoto Nakiri; Mitsunori Matsuo; Tsukasa Igawa
Oncology letters, 2019年06月

Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma.
Kosuke Ueda; Shigetaka Suekane; Hirofumi Kurose; Katsuaki Chikui; Makoto Nakiri; Kiyoaki Nishihara; Mitsunori Matsuo; Akihiko Kawahara; Hirohisa Yano; Tsukasa Igawa
Urologic oncology, 2018年11月

Efficacy of Axitinib as Second-line Treatment in Locally Advanced and Metastatic Renal Cell Carcinoma.
Kosuke Ueda; Shigetaka Suekane; Taishi Hirano; Naoyuki Ogasawara; Katsuaki Chikui; Keiichiro Uemura; Makoto Nakiri; Kiyoaki Nishihara; Mitsunori Matsuo; Tsukasa Igawa
Anticancer research, 2018年09月

Personalized peptide vaccination as second-line treatment for metastatic upper tract urothelial carcinoma
Shigetaka Suekane; Kousuke Ueda; Kiyoaki Nishihara; Tetsuro Sasada; Takuto Yamashita; Noriko Koga; Shigeru Yutani; Shigeki Shichijo; Kyogo Itoh; Tsukasa Igawa; Masanori Noguchi
CANCER SCIENCE, 2017年12月, ［査読有り］

Early primary renal tumor response predicts clinical outcome in patients with primary unresectable renal cell carcinoma with synchronous distant metastasis receiving molecularly targeted therapies.
Kosuke Ueda; Shigetaka Suekane; Kiyoaki Nishihara; Hiroki Suekane; Naoyuki Ogasawara; Hirofumi Kurose; Katsuaki Chikui; Kazuhisa Ejima; Shunsuke Suyama; Makoto Nakiri; Mitsunori Matsuo; Tsukasa Igawa
Molecular and clinical oncology, 2017年08月

Long-term response of over ten years with sorafenib monotherapy in metastatic renal cell carcinoma: a case report.
Kosuke Ueda; Shigetaka Suekane; Naoyuki Ogasawara; Katsuaki Chikui; Shunsuke Suyama; Makoto Nakiri; Kiyoaki Nishihara; Mitsunori Matsuo; Tsukasa Igawa
Journal of medical case reports, 2016年06月16日

Duration of First-line Treatment with Molecular Targeted-Therapy Is a Prognostic Factor in Metastatic Renal Cell Carcinoma.
Kosuke Ueda; Shigetaka Suekane; Kiyoaki Nishihara; Naoyuki Ogasawara; Hirofumi Kurose; Shuichiro Hayashi; Katsuaki Chikui; Shunsuke Suyama; Makoto Nakiri; Mitsunori Matsuo; Tsukasa Igawa
Anticancer research, 2015年06月

Successful treatment of erythropoietin-producing advanced renal cell carcinoma after targeted therapy using sunitinib: Case report and review of the literature.
Kosuke Ueda; Shigetaka Suekane; Katsuaki Chikui; Makoto Nakiri; Fukuko Moriya; Tokumasa Hayashi; Jiro Miyajima; Kei Matsuoka
Molecular and clinical oncology, 2013年01月

Phase I clinical study of a personalized peptide vaccination available for six different human leukocyte antigen (HLA-A2, -A3, -A11, -A24, -A31 and -A33)-positive patients with advanced cancer
Akira Yamada; Masanori Noguchi; Nobukazu Komatsu; Shigetaka Suekane; Shigeru Yutani; Fukuko Moriya; Takashi Mine; Kosuke Momozono; Koichiro Kawano; Kyogo Itoh
Experimental and Therapeutic Medicine, 2011年01月

Phase I clinical study of a personalized peptide vaccination available for six different human leukocyte antigen (HLA-A2, -A3, -A11, -A24, -A31 and -A33)-positive patients with advanced cancer.
Akira Yamada; Masanori Noguchi; Nobukazu Komatsu; Shigetaka Suekane; Shigeru Yutani; Fukuko Moriya; Takashi Mine; Kosuke Momozono; Koichiro Kawano; Kyogo Itoh
Experimental and therapeutic medicine, 2011年01月

2012年10月
米国泌尿器科学会(AUA)　　　　　　　　　　　　　　　

2007年08月
日本がん治療認定医機構　　　　　　　　　　　　　　　

2006年12月
日本移植学会　　　　　　　　　　　　　　　

2006年12月
日本内視鏡外科学会　　　　　　　　　　　　　　　

2006年04月
欧州泌尿器科学会(EAU)　　　　　　　　　　　　　　　

2004年
日本バイオセラピー学会　　　　　　　　　　　　　　　

2002年04月
日本癌治療学会　　　　　　　　　　　　　　　

1995年04月
日本Endourology and ESWL学会　　　　　　　　　　　　　　　

1993年04月
日本透析医学会　　　　　　　　　　　　　　　

1993年04月
日本臨床腎移植学会　　　　　　　　　　　　　　　

1991年05月
日本泌尿器科学会　　　　　　　　　　　　　　　

1991年05月
西日本泌尿器科学会　　　　　　　　　　　　　　　

進行性尿路がんに対する次世代個別化がんペプチドワクチン療法の開発
基盤研究(C)
久留米大学
2018年04月01日 - 2022年03月31日

標準治療抵抗性尿路上皮がん患者に対するペプチドワクチン療法のバイオマーカー検索
基盤研究(C)
久留米大学
2015年04月01日 - 2018年03月31日

腎癌ワクチン開発の基礎および臨床研究
若手研究(B)
久留米大学
2004年 - 2005年

精巣腫瘍浸潤キラーT細胞の解析と癌拒絶抗原遺伝子のクローニング
奨励研究(A)
久留米大学
1998年 - 1999年

特許第4392457号, 特願2008-542150, 組織切片作製用の切断ガイド装置及び組織切片作製装置
野口 正典; 末金 茂高; 松岡 啓

WO2008-053916, JP2007071202, 組織切片作製用の切断ガイド装置及び組織切片作製装置
野口 正典; 末金 茂高; 松岡 啓

超高齢化社会となり、がん患者が増加しています。泌尿器がんに対して、QOLを考慮した集学的治療法、特に複合がん免疫療法の更なる進化向上に努めてまりたいと思っています。排尿に関するお悩みにも対応いたします。

がん免疫療法の発展に期待しています。健康長寿を目指した下部尿路症状(LUTS)診療を地域の先生方とともに実践します。